Research programme: ghrelin receptor antagonists - COSCIENS Biopharma
Alternative Names: 1,2,4-Triazole based ghrelin receptor ligands as anti-obesity agents - COSCIENS Biopharma; AEZS-123; JMV 2760; JMV 2959; JMV 3018; JMV 3534Latest Information Update: 08 Aug 2024
Price :
$50 *
At a glance
- Originator Zentaris
- Developer AEterna Zentaris GmbH; AEterna Zentaris Inc; COSCIENS Biopharma; University of Milan; University of Montpellier I; University of Montpellier II; University of Montreal
- Class Small molecules; Triazoles
- Mechanism of Action Ghrelin receptor antagonists
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- No development reported Alcoholism; Obesity
Most Recent Events
- 06 Aug 2024 AEterna Zentaris Inc is now called COSCIENS Biopharma
- 04 Nov 2017 No recent reports of development identified for preclinical development in Obesity in Canada
- 04 Nov 2017 No recent reports of development identified for preclinical development in Obesity in France